PolyPid Ltd. Logo

PolyPid Ltd.

PYPD

(0.5)
Stock Price

3,22 USD

-126.5% ROA

-1219.71% ROE

-0.72x PER

Market Cap.

24.084.319,00 USD

589.44% DER

0% Yield

0% NPM

PolyPid Ltd. Stock Analysis

PolyPid Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PolyPid Ltd. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

2 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

3 ROE

Negative ROE (-298.63%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-105.51%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (20.74x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The company has a high debt to equity ratio (146%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

PolyPid Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PolyPid Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

PolyPid Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PolyPid Ltd. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PolyPid Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.377.000
2013 2.641.000 47.86%
2015 5.634.000 53.12%
2016 7.708.000 26.91%
2017 9.736.000 20.83%
2018 12.550.000 22.42%
2019 14.083.000 10.89%
2020 16.954.000 16.93%
2021 30.423.000 44.27%
2022 27.990.000 -8.69%
2023 15.224.000 -83.85%
2023 16.148.000 5.72%
2024 19.040.000 15.19%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PolyPid Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 410.000
2013 938.000 56.29%
2015 2.933.000 68.02%
2016 2.551.000 -14.97%
2017 4.064.000 37.23%
2018 5.265.000 22.81%
2019 4.477.000 -17.6%
2020 7.704.000 41.89%
2021 9.479.000 18.73%
2022 8.010.000 -18.34%
2023 4.772.000 -67.85%
2023 0 0%
2024 4.384.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PolyPid Ltd. EBITDA
Year EBITDA Growth
2012 -1.727.000
2013 -3.508.000 50.77%
2015 -11.168.000 68.59%
2016 -10.132.000 -10.23%
2017 -13.595.000 25.47%
2018 -42.150.000 67.75%
2019 -29.223.000 -44.24%
2020 -26.272.000 -11.23%
2021 -42.875.000 38.72%
2022 -38.888.000 -10.25%
2023 -21.040.000 -84.83%
2023 -21.045.000 0.02%
2024 -24.484.000 14.05%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PolyPid Ltd. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2015 -108.000 100%
2016 -127.000 14.96%
2017 -205.000 38.05%
2018 -411.000 50.12%
2019 -947.000 56.6%
2020 -1.012.000 6.42%
2021 -1.118.000 9.48%
2022 -1.721.000 35.04%
2023 0 0%
2023 -1.822.000 100%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PolyPid Ltd. Net Profit
Year Net Profit Growth
2012 -1.790.000
2013 -3.884.000 53.91%
2015 -8.220.000 52.75%
2016 -11.392.000 27.84%
2017 -54.488.000 79.09%
2018 5.917.000 1020.87%
2019 4.750.000 -24.57%
2020 -35.324.000 113.45%
2021 -40.713.000 13.24%
2022 -39.525.000 -3.01%
2023 -22.416.000 -76.32%
2023 -23.865.000 6.07%
2024 -25.176.000 5.21%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PolyPid Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -4
2013 -20 78.95%
2015 -19 -5.56%
2016 -39 52.63%
2017 -185 79.46%
2018 13 1523.08%
2019 11 -30%
2020 -111 109.09%
2021 -65 -69.23%
2022 -61 -6.56%
2023 -14 -369.23%
2023 -17 18.75%
2024 -5 -220%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PolyPid Ltd. Free Cashflow
Year Free Cashflow Growth
2012 -2.002.000
2013 -2.566.000 21.98%
2015 -6.686.000 61.62%
2016 -10.272.000 34.91%
2017 -14.196.000 27.64%
2018 -19.752.000 28.13%
2019 -18.237.000 -8.31%
2020 -22.772.000 19.91%
2021 -35.379.000 35.63%
2022 -36.084.000 1.95%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PolyPid Ltd. Operating Cashflow
Year Operating Cashflow Growth
2012 -1.857.000
2013 -2.518.000 26.25%
2015 -6.573.000 61.69%
2016 -9.733.000 32.47%
2017 -12.312.000 20.95%
2018 -16.678.000 26.18%
2019 -17.358.000 3.92%
2020 -21.596.000 19.62%
2021 -32.386.000 33.32%
2022 -34.317.000 5.63%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PolyPid Ltd. Capital Expenditure
Year Capital Expenditure Growth
2012 145.000
2013 48.000 -202.08%
2015 113.000 57.52%
2016 539.000 79.04%
2017 1.884.000 71.39%
2018 3.074.000 38.71%
2019 879.000 -249.72%
2020 1.176.000 25.26%
2021 2.993.000 60.71%
2022 1.767.000 -69.38%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PolyPid Ltd. Equity
Year Equity Growth
2012 -4.549.000
2013 -8.060.000 43.56%
2015 -231.000 -3389.18%
2016 -33.959.000 99.32%
2017 -88.646.000 61.69%
2018 -81.710.000 -8.49%
2019 30.935.000 364.13%
2020 72.777.000 57.49%
2021 36.230.000 -100.87%
2022 5.861.000 -518.15%
2023 3.538.000 -65.66%
2023 -2.096.000 268.8%
2024 1.601.000 230.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PolyPid Ltd. Assets
Year Assets Growth
2012 1.549.000
2013 1.959.000 20.93%
2015 2.480.000 21.01%
2016 19.237.000 87.11%
2017 22.984.000 16.3%
2018 14.484.000 -58.69%
2019 33.765.000 57.1%
2020 75.847.000 55.48%
2021 44.235.000 -71.46%
2022 25.971.000 -70.32%
2023 20.932.000 -24.07%
2023 15.372.000 -36.17%
2024 19.527.000 21.28%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PolyPid Ltd. Liabilities
Year Liabilities Growth
2012 6.098.000
2013 10.019.000 39.14%
2015 2.711.000 -269.57%
2016 53.196.000 94.9%
2017 111.630.000 52.35%
2018 96.194.000 -16.05%
2019 2.830.000 -3299.08%
2020 3.070.000 7.82%
2021 8.005.000 61.65%
2022 20.110.000 60.19%
2023 17.394.000 -15.61%
2023 17.468.000 0.42%
2024 17.926.000 2.55%

PolyPid Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-4.92
Price to Earning Ratio
-0.72x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
11.11
EV to Sales
0
EV Over EBITDA
-1.35
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-1.39
FreeCashFlow Yield
0
Market Cap
0,02 Bil.
Enterprise Value
0,03 Bil.
Graham Number
5.94
Graham NetNet
-1.67

Income Statement Metrics

Net Income per Share
-4.92
Income Quality
0
ROE
-9.7
Return On Assets
-1.37
Return On Capital Employed
-2.83
Net Income per EBT
1
EBT Per Ebit
1.04
Ebit per Revenue
0
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-2.15
Return on Tangible Assets
-1.27
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,89
Book Value per Share
0,32
Tangible Book Value per Share
0.32
Shareholders Equity per Share
0.32
Interest Debt per Share
2.07
Debt to Equity
5.89
Debt to Assets
0.48
Net Debt to EBITDA
-0.33
Current Ratio
0.95
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
8984000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.39

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PolyPid Ltd. Dividends
Year Dividends Growth

PolyPid Ltd. Profile

About PolyPid Ltd.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

CEO
Ms. Dikla Czaczkes Akselbrad
Employee
59
Address
18 Hasivim Street
Petah Tikva, 4959376

PolyPid Ltd. Executives & BODs

PolyPid Ltd. Executives & BODs
# Name Age
1 Mr. Ori Warshavsky
Chief Operating Officer - US
70
2 Mr. Jonny Missulawin
Chief Financial Officer
70
3 Mr. Tal Vilnai
General Counsel & Corporate Secretary
70
4 Ms. Dalit Hazan
Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs
70
5 Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer & Director
70
6 Ms. Maria Rubin
Vice President of Operations
70
7 Ms. Rivi Lev-ari
Vice President of Human Resource
70
8 Dr. Jean-Marc Hagai Pharm.D.
Chief Commercial Officer
70

PolyPid Ltd. Competitors